Silexion Therapeutics Reports Positive Initial Data from Sil204 in Pancreatic Cancer Models
Silexion Therapeutics (NASDAQ: SLXN) has released positive preclinical data for SIL204, its RNAi therapy targeting KRAS-driven cancers. The study...
eClinical Tech News
Zyversa Demonstrates NLRP3 Inhibition Improves Heart Function, Glucose Homeostasis, and Insulin Sensitivity in Obese Animal Model
ZyVersa Therapeutics highlighted newly published data demonstrating the cardioprotective and metabolic benefits of inhibiting NLRP3 inflammasome pathways in an...
Invivyd Announces Neutralizing Activity of Pemigarda Against Dominant SARS-CoV-2 Variant
Invivyd announced positive in vitro neutralization data for its COVID-19 antibody treatment, PEMGARDA (pemivibart), against the dominant LP.8.1 variant....
Garuda Therapeutics Secures $50M to Advance Blood Stem Cell Therapies
Garuda Therapeutics secured $50 million in Series A-1 funding to develop off-the-shelf hematopoietic stem cell (HSC) therapies for various...
Enlivex Therapeutics Announces Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
Enlivex Therapeutics announced positive interim six-month data from its Phase I/II Allocetra™ trial for knee osteoarthritis. The trial showed...
Celon Pharma Promising Phase 2 Data for PDE10A Inhibitor in Parkinson’s Dyskinesia
Celon Pharma announced positive Phase 2 clinical trial results for its oral, once-daily PDE10A inhibitor, CPL’36, for treating Levodopa-Induced...
Cingulate ADHD Drug Shows Promise in Phase 3 Trials
Cingulate Inc. released positive Phase 3 safety data for CTx-1301 (dexmethylphenidate), its once-daily ADHD treatment. The data, encompassing pediatric...
Tiziana Life Sciences Files IND Application with FDA for ALS Phase 2 Trial
Tiziana Life SciencesLife Sciences has submitted an Investigational New Drug (IND) application to the FDA for a phase 2...
Nuvectis Pharma: Combination Therapy Improves EGFR Inhibitor Efficacy
Nuvectis Pharma announced promising preclinical research demonstrating the synergistic effects of combining its drug candidate, NXP900, with osimertinib (Tagrisso®)...
Cybrexa Unveils Promising Preclinical Data on Tumor-Selective PDCs at ESMO 2025
Cybrexa Therapeutics presented preclinical data at the ESMO Targeted Anticancer Therapies Congress 2025, showcasing their alphalex™ peptide-drug conjugates (PDCs)....